ZEPHYR AI
LIVE

Serial Number

97524671

Owner

Zephyr AI, Inc

Attorney

Karen Won

Filing Date

Jul 28, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ZEPHYR AI Trademark

Serial Number: 97524671

ZEPHYR AI is a trademark filed by Zephyr AI, Inc on July 28, 2022. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Zephyr AI, Inc

3889 Maple Avenue, Suite 500
Dallas, TX 75219

Entity Type: 03

Trademark Details

Filing Date

July 28, 2022

Registration Date

Not Registered

Published for Opposition

September 26, 2023

Goods & Services

Scientific research consulting services in the fields of healthcare, medicine, genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; scientific and medical research analysis of healthcare, medical, genetic, scientific, biologic, clinical and oncologic data; scientific research consulting in the fields of healthcare, medicine, genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; genetic and tumor mapping for scientific and medical research purposes; providing medical and scientific research information in the fields of genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; drug discovery services; scientific services, namely, analyzing medical, genetic, oncological, biological and diabetes-related data for treatment and diagnostic purposes by using machine learning and artificial intelligence technologies; providing scientific, medical and clinical research and scientific, medical and clinical research consulting services in the fields of healthcare, medicine, genetics, oncology, biology, life sciences, biotechnology, drug development, and pharmaceuticals by using machine learning, artificial intelligence technology, and biotechnology; medical and scientific research and consulting, namely, designing and organizing clinical trials for others; research and development services in the creation of databases and collections of information and data on biologicals for research purposes; providing genetic reference databases being collections of gene sequences for research purposes; disease modeling for research purposes; scientific analysis services, namely, services using computer algorithms for analysis of bioinformatics data in the field of research and development of therapeutic biomolecules for the treatment of cancer, diabetes, and other diseases; pharmaceutical drug development services; genetic research for identifying biomarker rankings for medical purposes; research and development of pharmaceutical preparations and medicines; consulting services in the field of pharmaceutical research and development; medical and scientific research in the field of medical treatment and diagnosis, including for cancer and diabetes; providing temporary use of online non-downloadable software, cloud-based software, platform as a service (PAAS) featuring computer software platforms, and a website featuring technology, all for enabling users to use artificial intelligence for machine learning in the fields of healthcare, medicine, genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; software design and development; software installation and maintenance; DNA analysis services for scientific and medical research purposes; application service provider (ASP) featuring software using artificial intelligence for machine learning

Downloadable computer programs using artificial intelligence for machine learning; downloadable software using artificial intelligence for machine learning for scientific and medical research and development; downloadable computer software, software platforms, downloadable mobile applications, and downloadable software programs using artificial intelligence and machine learning technologies for scientific and medical research and development; downloadable computer programs using artificial intelligence for machine learning in the fields of healthcare, medicine, genetics, oncology, biology, life sciences, biotechnology, drug development, and pharmaceuticals

Healthcare;medical services;consulting services in the field of healthcare, medicine, and medical use of pharmaceuticals; healthcare, medical, and pharmaceutical medical use information services; DNA screening for medical purposes; clinical medical consultation services; healthcare, medical, and pharmaceutical services, namely, providing databases in the fields of medical, scientific, genetic, oncological, and biological information for inputting, collecting, analyzing, and managing data for treatment and diagnostic purposes; healthcare and medical services, namely, analyzing medical, genetic, oncological, biological and diabetes-related data for treatment and diagnostic purposes by using machine learning and artificial intelligence technologies; providing medical consulting services in the fields of healthcare, medicine, genetics, oncology, biology, life sciences, biotechnology, drug development, and pharmaceuticals by using machine learning, artificial intelligence technology, and biotechnology

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 22, 2026 EXRA
SOU EXTENSION 5 GRANTED
May 21, 2026 EX5G
SOU TEAS EXTENSION RECEIVED
May 20, 2026 EEXT
SOU EXTENSION 5 FILED
May 19, 2026 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 19, 2025 EXRA
SOU EXTENSION 4 GRANTED
Nov 18, 2025 EX4G
SOU EXTENSION 4 FILED
Nov 18, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Nov 18, 2025 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 8, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 8, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 8, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 8, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 8, 2025 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 22, 2025 EXRA
SOU EXTENSION 3 GRANTED
Mar 21, 2025 EX3G
SOU EXTENSION 3 FILED
Mar 21, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 21, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 14, 2025 EXRA
SOU EXTENSION 2 GRANTED
Feb 13, 2025 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 13, 2025 AITU
SOU EXTENSION 2 FILED
Nov 19, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 19, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 4, 2024 EXRA
SOU EXTENSION 1 GRANTED
May 3, 2024 EX1G
SOU EXTENSION 1 FILED
May 3, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
May 3, 2024 EEXT
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 22, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 22, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 22, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 22, 2024 REAP
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 21, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 26, 2023 NPUB
PUBLISHED FOR OPPOSITION
Sep 26, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 6, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 22, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 22, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 22, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 22, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 22, 2023 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 14, 2023 GNFN
FINAL REFUSAL E-MAILED
Aug 14, 2023 GNFR
FINAL REFUSAL WRITTEN
Aug 14, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 14, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 13, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 13, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 17, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 17, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 17, 2023 CNRT
ASSIGNED TO EXAMINER
May 15, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 1, 2022 NWOS
NEW APPLICATION ENTERED
Aug 1, 2022 NWAP